Bajaj Healthcare shares rise 7%; co enters into API development, supply agreement with European entity

Bajaj Healthcare Ltd

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Bajaj Healthcare's shares rose nearly 7 percent around noon after the company informed the exchanges that it has entered into a development and supply agreement with a European entity for an Active Pharmaceutical Ingredient (API).

At 12.50 PM, Bajaj Healthcare's shares traded nearly 5 percent higher at Rs 395. In the past six months, the stock has gained over 33 percent, outperforming the Nifty 50 which gained 17 percent during the same period. The stock has been giving positive monthly returns since June.

Bajaj Healthcare said that initially, the API will be supplied in small quantities for clinical trials, where it will be tested for an alternative indication.

Follow our live blog for all the market action

"The trust reposed in our Company by the EU partner for sourcing clinical trial quantities is a testimony
of the Company's development and manufacturing capabilities along with the Good Manufacturing
Practices (GMP) compliance at Company's manufacturing units," Bajaj Healthcare said in the filing.

Once the trials are successfully completed, full-scale supply will begin from the company's FDA-approved facility in Savli, Vadodara. Until the trial outcomes are finalised, the agreement is expected to be revenue-neutral.

Incorporated in 1993, Bajaj Healthcare manufactures a wide range of APIs and formulations.

Bajaj Healthcare announced its Q1 FY24 results on August 14, reporting a 1.9 percent year-on-year revenue growth and a profit of Rs 7.13 crore, a sharp recovery from a Rs 48.2 crore loss in the same period last year. However, revenue declined 1.2 percent compared to the previous quarter.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.